Salmeterol/fluticasone combination in the treatment of COPD by Chung, K F
International Journal of COPD 2006:1(3) 235–242
© 2006 Dove Medical Press Limited. All rights reserved
235
REVIEW
Abstract: Clinical trials of a combination therapy of an inhaled corticosteroid, ﬂ  uticasone 
propionate (FP), with a long-acting β2-agonist, salmeterol (Sal), have demonstrated a greater 
improvement in lung function and in quality of life measures after the combination compared 
with either component of alone. In a subanalysis of the data of the TRISTAN study, Sal/FP 
reduced exacerbation rates in COPD patients with a baseline FEV1<50% of predicted. A 
combination therapy of budesonide and formoterol improved quality of life and FEV1, and 
reduced exacerbations better than either component alone. In studies of FP or of Sal/FP in 
COPD, there was a reduction in all-cause mortality by 25% relative to placebo. Sal/FP has 
anti-inﬂ  ammatory effects in COPD airways. FP inhibits markers of systemic inﬂ  ammation, and 
it is not known whether Sal/FP has an advantage over FP alone. While long-acting β2-agonists 
such as Sal can be recommended for treatment of moderate COPD, addition of inhaled steroid 
therapy such as FP should be considered in more severe disease. 
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Introduction
COPD is a disease of the airways and lungs characterized by a chronic inﬂ  ammatory 
process, in which patients develop a progressive loss of lung function (eg, a fall in 
FEV1) and symptoms of breathlessness sometimes associated with chronic sputum 
production, leading to a reduction in quality of life measures. There is a wide spectrum 
of disease severity ranging from asymptomatic patients to those with severe capacity 
disease, recurrent exacerbations, and a higher risk of death. The categorization of 
COPD severity has been described in the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD), based essentially on the level of airﬂ  ow obstruction measured 
with FEV1 and on the presence of symptoms. It consists of at-risk (Stage 0, normal 
lung function with chronic productive cough), mild (Stage 1: FEV1/FVC<70%; 
FEV1>80% of predicted), moderate (Stage II: 50%<FEV1<80% of predicted with 
shortness of breath on exertion), severe (Stage III: 30%<FEV1<50% of predicted with 
increasing shortness of breath and repeated exacerbations), and very severe (Stage 
IV: <30% of predicted or chronic respiratory failure) (see http://www.goldcopd.
com/Guidelineitem.asp?l1=2&l2=1&intId=996). In most cases, cigarette smoking 
is directly linked to the development of COPD, although at-risk factors may also be 
involved such as environmental air pollution and respiratory infections. A diagnosis 
of COPD needs to be considered in current or ex-smokers who present with cough, 
sputum production, and shortness of breath, associated with spirometric evidence of 
irreversible airﬂ  ow obstruction. 
COPD is a more complex disease than just an afﬂ  iction of the airways and 
lungs. It is a multi-system disease that includes systemic inﬂ  ammation, oxidative 
stress, skeletal muscle dysfunction, and cardiovascular disease, among others. 
Other scores have been developed in an attempt to encompass the multi-system 
aspects of COPD. One such score is the BODE index that includes assessment of 
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four factors in the disease: body mass index (B), airﬂ  ow 
obstruction (O), dyspnea (D), and exercise capacity (E). 
This index has been particularly useful in predicting 
survival, and was shown to be better than spirometric 
measures (Celli et al 2004). Therefore, in terms of 
beneﬁ  cial effects of anti-COPD therapies, it is not only 
necessary to determine their effects on lung function or 
respiratory symptoms but also on other components of this 
multisystem disorder.
Treatments for COPD
Treatments for COPD have remained purely on a 
symptomatic basis: relief of symptoms of breathlessness 
through reducing airflow obstruction, relying mostly 
on the use of inhaled bronchodilator therapy including 
β2-adrenergic agonists and anticholinergics. The recent 
introduction of long-acting β2-agonists (LABA) and long-
acting anticholinergics (LAA) has led to an improvement in 
the management of patients with COPD, allowing for more 
sustained bronchodilation and symptom relief. The utility 
of inhaled corticosteroid therapy in COPD, in contrast 
to its well-established use in asthma, remains somewhat 
controversial. Large studies of inhaled corticosteroids 
(ICS) in COPD indicate that it has no effect in modifying 
the rate of decline in lung function (FEV1) in 3-year-
long studies (Bourbeau et al 1998; Pauwels et al 1999; 
Vestbo et al 1999; Burge et al 2000; Lung Health Study 
Research Group 2000). There was a small improvement, 
however, on post-bronchodilator FEV1 in two of the 
studies (Pauwels et al 1999; Burge et al 2000). However, 
fluticasone propionate can reduce exacerbation rates 
(Burge et al 2000). The lack of effect of corticosteroids 
in COPD (on yearly decline) could reﬂ  ect (a) a relative 
resistance to corticosteroids, as demonstrated in this 
disease with alveolar macrophages or (b) an inﬂ  ammatory 
component that is unique in severe COPD that is not 
inhibited by corticosteroids, or inability to enhance a 
natural anti-inﬂ  ammatory pathway or (c) the chronic 
bronchial and pulmonary inﬂ  ammation is at a stage that 
is irreversible. 
Combination therapy
This review will examine the effect of a salmeterol/
fluticasone propionate (Sal/FP) combination therapy in 
COPD. To do so, it is important ﬁ  rst to review the effects 
of each of these components separately on COPD, and 
to determine whether the combination has additive or 
synergistic effects. The role of the LABA, Sal, (Appleton 
et al 2000; Jarvis and Markham 2001) and that of the ICS, 
FP (Sin et al 2003; Donohue and Ohar 2004), in the treatment 
of COPD has already been reviewed. 
Clinical trials of Sal/FP in COPD
Mahler et al (2002) reported that in 691 patients with 
COPD who received either the combination of FP (500 μg 
twice daily) and Sal (50 μg twice daily), or FP alone, or 
Sal alone, or placebo twice daily via the multi-dose drug 
powder inhaler Diskus
® device (GlaxoSmithKline Inc., 
Research Triangle Park, NC, USA) for 24 weeks, there 
was a significantly greater increase in pre-dose FEV1 
at the endpoint after combination (156 mL) compared 
with Sal (107 mL, p=0.012), with FP (109 mL; p=0.038) 
and placebo (–4 mL, p<0.0001). A greater increase in 
2-hour post-dose FEV1 at the endpoint was observed after 
treatment with combination (261 mL) compared with FP 
(138 mL, p<0.001) and placebo (28 mL, p<0.001), but 
not with Sal (221 mL). There were greater improvements 
in the Transition Dyspnea Index (TDI), a measure of 
the degree of breathlessness, with combination (2.1) 
compared with FP (1.3, p=0.033), Sal (0.9, p<0.001), 
and placebo (0.4, p<0.0001). Treatment with combination 
resulted in a clinically important increase from baseline 
in overall Chronic Respiratory Disease Questionnaire 
(CRDQ) score that was significantly greater compared 
with that of placebo and FP, but to that of Sal (Mahler 
et al 2002)
Hanania et al (2003) reported a similarly designed 
24-week study of 732 patients with nearly similar results 
regarding the pre- and post-dose FEV1, TDI, CRDQ, and 
PEFR, using a lower dose of FP of 250 μg twice daily with 
Sal 50 μg twice daily. They also reported that the effects on 
airway function were observed within 24 hours after start of 
therapy. In the TRISTAN study (Trial of Inhaled Steroids and 
Long-acting β2-Agonists), the effects of Sal and FP alone or 
in combination on peak expiratory ﬂ  ows and breathlessness 
were seen within the ﬁ  rst 2 days and for FEV1 and PEF, 
the maximum response appeared within 2 weeks (Vestbo 
et al 2005). A small study suggested that Sal/FP improved 
FEV1 in mild-moderate more than in severe COPD patients 
(Terzano et al 2005). 
Make et al (2005) conducted a shorter 8-week, 
multicentre, randomized, double-blind, double-dummy, 
parallel-group study of 361 subjects with moderate-to-
severe COPD to compare Sal/FP 50/250 μg twice daily with 
the combined bronchodilator ipratropium and salbutamol 
36/206 μg twice daily (Make et al 2005). They found that International Journal of COPD 2006:1(3) 237
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combination resulted in greater improvements in morning 
pre-dose FEV1, morning PEF, and 6-hour area-under-the-
curve (AUC) FEV1 (all p<0.001), TDI score (p=0.026), 
overall daytime symptom score (p=0.024), percentage of 
symptom-free nights (p=0.010), night time awakenings 
due to respiratory symptoms (p=0.002), sleep symptom 
score (p=0.003), and percentage of days and nights without 
rescue salbutamol use compared with the bronchodilator 
combination (p=0.021 and p<0.001, respectively). There 
was greater bronchodilatation measured at the 8th week 
of treatment. Thus, compared with day 1, the FEV1 AUC 
at week 8 increased by 0.38 litre-hour with combination 
therapy and decreased by 0.18 litre-hour with bronchodilator 
combination (p<0.001 between groups) (Make et al 2005) 
Short-term treatment with inhaled Sal/FP resulted in greater 
control of lung function and symptoms than combined 
ipratropium bromide/salbutamol bronchodilator therapy, in 
patients with COPD (Donohue et al 2004).
The TRISTAN study was a double-blind, parallel-
group, placebo-controlled study involving 1465 patients 
with COPD comparing the effects of either 50 μg Sal 
twice daily, 500 μg FP twice daily, 50 μg Sal and 500 μg 
FP twice daily, or placebo for 12 months, all administered 
via the Diskus inhaler (Calverley et al 2003a). All active 
treatments improved lung function, symptoms, and health 
status and reduced use of rescue medication and frequency 
of exacerbations. Combination therapy was better than 
FP alone or Sal alone in terms of pre-treatment and post-
bronchodilator FEV1 (the primary outcome measurement) 
and PEF but not in terms of exacerbation rates (Figure 1). 
Compared with placebo, all active treatments signiﬁ  cantly 
reduced the number of exacerbations per patient per year 
and the number of exacerbations that needed treatment with 
oral corticosteroids. The rate of exacerbations fell by 25% 
in the combination group, by 20% in the Sal group, and by 
19% in the FP group, compared with placebo (Figure 2). 
On subanalysis of the data, the treatment effect was more 
pronounced in patients with a baseline FEV1 <50% of 
predicted. The reduction in acute episodes of exacerbations 
requiring oral corticosteroids was reduced by 39% in the 
combination group, 29% in the Sal group, and 34% in FP 
group compared with placebo, with no statistical differences 
between the treatments. 
In a study of only 18 patients with COPD observed 
over 52 weeks, a marked decrease in exacerbations (from 
3.5±0.8 to 1.2±0.8 exacerbations per year) was reported 
when patients previously treated with theophylline were 
switched to a Sal/FP inhaler, but not when switched to 
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Figure 1 Mean changes from baseline of prebronchodilator FEV1 (A), 
postbronchodilator FEV1 (B), daily peak expiratoiry ﬂ  ows (C), and St Georges’ 
health status scores (D) in the TRISTAN study. Reprinted from Calverley P, 
Pauwels R, Vestbo J, et al. 2003a. Combined salmeterol and ﬂ  uticasone in the 
treatment of chronic obstructive pulmonary disease: a randomised controlled trial. 
Lancet, 361:449–56. Coypright © 2003 with permission from Elsevier.International Journal of COPD 2006:1(3) 238
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Sal or placebo. This was associated with an improvement 
of FEV1 of 7.3% (Dal Negro et al 2003). Which of the 
two components of combination therapy is important has 
been studied in studies in which either component has been 
withdrawn. Withdrawing the FP component of Sal/FP after 
a 3-month period of treatment led to an acute and persistent 
reduction in lung function and dyspnea, and an increase 
in mild exacerbations and % of disturbed nights (Wouters 
et al 2005). These results are somewhat similar to those 
of the COPE study in which patients were using only FP: 
withdrawal of the FP led to worsening of symptoms (van der 
Valk et al 2002). Re-analysis of the TRISTAN data indicated 
that gender did not inﬂ  uence the response to Sal/FP in COPD 
(Vestbo et al 2004).
Combination of budesonide and
formoterol in COPD
There are two published studies of the combination of 
budesonide and formoterol inhaler delivered from the 
multidose dry powder inhaler device (Turbohaler
®) in 
COPD. Szafranski et al (2003) found a small nonstatistical 
improvement in FEV1 with budesonide/formoterol 
(160/4.5 μg delivered dose; two inhlations twice daily) over 
formoterol alone, while signiﬁ  cantly better than budesonide 
alone (p<0.001); however, the combination therapy was 
better than either one alone for morning or evening PEFR. 
The combination decreased all symptoms scores and use of 
reliever β2-agonist signiﬁ  cantly vs placebo and budesonide, 
but not vs formoterol alone. The combination reduced the 
mean number of severe exacerbations per patient per year by 
24% vs placebo, and 23% vs formoterol, with a signiﬁ  cant 
difference vs budesonide.
In a second 12-month study of the combination of 
budesonide and formoterol, in which the patients were ﬁ  rst 
treated with prednisolone 30 mg/day and formoterol for 2 
weeks prior to randomization, Calverley et al (2003b), using 
a similar dose of budesonide/formoterol as Szafranski et al 
(2003), report that the combination prolonged the time to 
ﬁ  rst exacerbation and maintained higher FEV1 better than 
budesonide or formoterol alone. The combination reduced 
the risk of having an exacerbation by 22.7, 29.5, and 28.5% 
vs budesonide, formoterol, and placebo respectively. 
Budesonide and formoterol alone did not affect exacerbation 
rate vs placebo. The combination also improved quality of life 
scores measured on the St Georges Respiratory Questionnaire 
(SGRQ) better than either alone, with an improvement of 
greater than 5.5 units compared to placebo.
There is only one small study of 16 patients with COPD 
comparing the combination of Sal/FP with budesonide/
formoterol using a crossover design (Cazzola et al 2003). 
No difference in FEV1 response was observed, and efﬁ  cacy 
and safety were deemed to be equivalent, but there has been 
no study on exacerbation rates. Such a study is too small to 
detect any small differences.
Systematic meta-analysis reviews
Systematic review of combination therapy with Sal/FP and 
budesonide/formoterol has been reported by Sin et al (2003) 
(3 studies, 2951 patients) and by Nannini et al (2004) (6 
studies, 4118 patients). Nannini et al (2004) concluded that 
combination therapy was better than placebo, with clinically 
important improvement in lung function, mean exacerbation 
rate, and quality of life scores. For lung function, there were 
signiﬁ  cant differences of combination therapy vs ICS alone, 
with Sal/FP better than Sal alone, but with budesonide/
formoterol equal to formoterol alone. Analysis of all 
studies showed that there were less frequent exacerbations 
with combination therapy than with placebo or Sal, but not 
when compared with the FP alone. Nannini et al found that 
in comparison with long-acting β2-agonists, there was no 
signiﬁ  cant difference between budesonide and formoterol, 
and FP and Sal. However, compared with their constituent 
long-acting β2-agonist, there was a signiﬁ  cant reduction 
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Figure 2 Cumulative risk of acute exacerbations in the TRISTAN study. There 
were no differences between the three active treatment groups. Reprinted from 
Calverley P, Pauwels R, Vestbo J, et al. 2003a. Combined salmeterol and ﬂ  utica-
sone in the treatment of chronic obstructive pulmonary disease: a randomised 
controlled trial. Lancet, 361:449–56. Coypright © 2003 with permission from 
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in exacerbation rate for the budesonide/formoterol 
combination but not for the Sal/FP combination. The rate-
ratio of exacerbation rates for Sal/FP compared with Sal 
was 0.93 (0.81–1.08, 95% conﬁ  dence interval), and for the 
combination of budesonide and formoterol compared with 
formoterol alone 0.76 (0.64–0.90). In COPD patients with 
a history of one or more exacerbations in the previous year, 
the difference of 24% could translate to one exacerbation 
less every 4 years.
A recent report calculated the number of patients needed 
to treat (NNT) to avoid one exacerbation requiring medical 
intervention in one year with budesonide and formoterol 
vs formoterol alone to be 2.38 in the Szafranski study 
(Szafranski et al 2003) and 2.13 in the Calverley study 
(Calverley et al 2003b), with corresponding values vs 
placebo being 2.22 and 2.38 respectively (Halpin 2005). In 
the same paper, an NNT value of 3.03 was obtained for the 
TRISTAN study for the prevention of exacerbations by the 
Sal/FP combination vs placebo. 
Effect on survival
Although inhaled corticosteroids do not have an effect 
on the rate of decline of FEV1, observational studies of 
COPD databases have suggested that ICS either alone or 
in combination with long-acting β2-agonists may reduce 
mortality rates in COPD (Sin and Tu 2001; Soriano et al 
2002, 2003). Another study did not show this advantage 
when data are analyzed according to an according-to-treat 
approach and the survival beneﬁ  t of the previous studies 
was attributed to bias from unaccounted immortal time in 
the cohort design and analysis (Suissa 2004). The effects of 
Sal/FP or of budesonide/formoterol on mortality are unclear, 
but in an earlier meta-analysis of placebo-controlled studies, 
the relative risk of combination therapy vs placebo was 
found to be 0.52 (0.20–1.34) (Alsaeedi et al 2002). In a more 
recent meta-analysis from pooled data from 7 randomized 
trials involving 5058 patients taking ICS with or without 
LABA, active treatment reduced all-cause mortality by 25% 
relative to placebo during a mean follow-up of 26 months 
(Sin et al 2005). The effect of combination therapy and of its 
components alone on survival rate is being investigated in 
the TORCH trial (Towards a Revolution in COPD Health) 
(Vestbo 2004). 
Safety and tolerability of Sal/FP
In all the studies with Sal/FP lasting for 8–48 weeks of 
therapy, the combination therapy was well tolerated. 
There were no differences between groups in the adverse 
event reports. In all the studies, there was greater incidence 
of candidiasis in the FP only or the combined Sal/FP treated 
groups compared with placebo and Sal groups. In the one 
year TRISTAN study, the frequency of candidiasis in the FP 
group was 7%, and in the combination group 8% compared 
with 2% in both placebo and Sal groups (Donohue and Ohar 
2004). Morning cortisols decreased during FP and during 
combination therapy, while they increased in the placebo 
and Sal groups, after 52 weeks of treatment, but these 
changes were small and levels remained within the normal 
reference values. There was no difference in skin bruising 
between the groups. 
The long-term side-effects of inhaled corticosteroids 
in COPD are unclear and further work is needed, since 
the population of COPD is generally an elderly population 
in which risk of side-effects may be greater than in a 
younger population exposed to similar doses of inhaled 
corticosteroids. In addition, these patients who are at the 
severe end of the disease may also have a greater risk of 
steroid side-effects, as they are more likely to be exposed 
to courses of oral corticosteroid therapy for treatment of 
exacerbations. 
The dose-response of FP in the Sal/FP combination in 
COPD is unclear. From the studies of Make et al (2005), 
Hanania et al (2003), and Mahler et al (2002), it appears 
that there is little difference in effect on symptom response 
between 500 μg and 1000 μg per day dosage, but there is 
only one study on the effect of Sal/FP on exacerbations 
using 1000 μg daily dose (Calverley et al 2003a). The dose-
response effect on reduction of exacerbations needs to be 
clariﬁ  ed.
Effect of Sal/FP on pulmonary and 
systemic inﬂ  ammation
The effect of Sal/FP on airway inﬂ  ammation measured in 
bronchial biopsies has been reported recently (Barnes et al 
2006). Compared with placebo treatment, combination 
therapy reduced CD8+T cells by a median treatment 
difference of 118 cells/mm
2 (36% reduction; p=0.02) from 
baseline, and CD4+ T cells by 45 cells/mm
2 (40% reduction, 
p=0.017), but the ratio of CD8/CD4 was unchanged. 
There was a small decrease in neutrophil counts in the 
Sal/FP-treated group. Prebronchodilator FEV1 improved 
by 173 mL after Sal/FP (p<0.001), and exacerbation rate 
was reduced by 33% compared with a 16% reduction after 
placebo (p=0.025). In addition, there was a signiﬁ  cant 
reduction in the percentage of (but not total) neutrophils International Journal of COPD 2006:1(3) 240
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in induced sputum of –53% in the Sal/FP therapy group 
compared with placebo. These results indicate that Sal/FP 
may possess anti-inﬂ  ammatory effects in COPD, although 
the contribution of FP alone to these effects is unknown. In 
addition, because there was no comparative group treated 
with either FP or Sal alone, it is not possible to answer 
the question as to whether there was an additive effect of 
these two classes of drugs when administered together on 
inﬂ  ammation. Were the clinical beneﬁ  ts of Sal/FP related to 
an anti-inﬂ  ammatory effect rather than a “bronchodilator” 
effect? Post hoc evaluation of correlations between lung 
function (change
 in FEV1 as percentage of predicted 
normal and change in FVC)
 and primary and secondary 
biopsy parameters showed no convincing
 or signiﬁ  cant 
correlations in the Barnes et al (2006) study. While these 
data on inﬂ  ammatory cells in bronchial biopsies from 
the proximal airways are important, it is more pertinent 
to obtain information on the pathophysiological changes 
related to the small airways, where the airﬂ  ow obstruction 
is the most prominent. 
In a previous biopsy study, inhaled FP was shown to 
reduce the ratio of CD4 to CD8 T cells in the epithelium 
of patients with COPD, with a reduction in epithelial 
mast cells (Hattotuwa et al 2002); in another paper, these 
investigators also described a reduction in mucosal mast 
cell numbers (Gizycki et al 2002). In a study of induced 
sputum, the number of neutrophils was significantly 
lowered after FP (Confalonieri et al 1998), although 
another study did not report any significant changes 
(Culpitt et al 1999). 
Further support for an effect of ICS in inhibiting 
inﬂ  ammation of COPD comes from a study of serum CRP 
levels which are elevated in COPD. Withdrawal of ICS from 
patients with COPD established on ICS led to an increase in 
serum CRP levels, while 2 weeks of inhaled FP decreased 
serum CRP and IL-6 levels by 50% and 26% respectively 
(Sin et al 2004). A large study, the Advair Biomarkers in 
COPD (ABC study), will address the question of whether 
the effects of FP alone or in combination with Sal reduce 
systemic inﬂ  ammation and improve health status in patients 
with COPD (Sin et al 2006). This study may provide direct 
evidence for the importance of systemic inﬂ  ammation in 
determining the severity of symptoms and deterioration in 
health status in COPD. Whether the effects of Sal/FP on 
systemic inﬂ  ammation are secondary to a systemic effect of 
inhaled FP or whether the control of systemic inﬂ  ammation 
is the result of an effect on local lung inﬂ  ammation may be 
important to determine.
Molecular basis for the actions of
Sal/FP
The molecular basis for the superiority of combined LABA 
and ICS on the control of symptoms and lung function 
improvement compared with the effect of either alone 
in COPD has been reviewed recently (Johnson 2005). 
The major effects could result from interactions between 
ICS and LABA such as (i) the increase in β2-receptor 
synthesis induced by corticosteroids, (ii) the priming of 
glucocorticoid receptor for steroid-dependent activation 
by LABA (Eickelberg et al 1999), or (iii) the enhancement 
of glucocorticoid receptor nuclear translocation via the 
activation of the transcription factor CEBP-α (Roth 
et al 2002). However, more work is needed to establish 
whether these mechanisms actually occur in patients 
but there has been clear advances in our understanding 
of corticosteroid insensitivity over the recent years (Ito 
et al 2006). It is also possible that β2-agonists may restore 
to some extent the glucocorticoid insensitivity found in 
COPD resulting from excessive oxidative stress (Adcock 
and Chung 2002).
Clinical recommendation and 
conclusion
Bronchodilators remain central to the symptomatic treatment 
of COPD as they increase exercise capacity with or without 
signiﬁ  cant changes in FEV1, and improve health status. 
Patients with mild to moderate COPD may progress from 
short-acting bronchodilators (β2-agonist, or anticholinergics, 
or a combination of the two) to long-acting bronchodilators 
(LABA or LAA) if they do not respond to the former. ICS 
may be added to bronchodilator therapy for the more severe 
COPD patient particularly for those with an FEV1 of <50% 
predicted at stage III and stage IV, and those with frequent 
exacerbations. ICS with long-acting β-agonists such as Sal/
FP is more effective particularly for control of symptoms 
and improving health status, and should be reserved for the 
severe COPD patient, and for patients at stage III and stage 
IV, when bronchodilators alone have not been successful 
(Table 1). 
Further work is needed in order to place more 
precisely the role of combination therapy such as Sal/FP 
in the management of COPD. The issue of the dose–
response relationship, particularly in relation to the dose 
of FP, is important to resolve because the population 
of COPD patients may be more prone to the potential 
systemic side-effects of FP, particularly as the high daily International Journal of COPD 2006:1(3) 241
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dose of 1000 μg of FP has been most frequently studied. It 
is also possible that the symptoms or quality of life measures 
may respond at a different dose schedule than the rate of 
exacerbations. While the current recommendations have been 
based mostly on the results of clinical trials, the potential 
beneﬁ  cial effects of combination  therapy  on  all-cause   
mortality  may  lead to changes in these recommendations. 
Similarly, conﬁ  rmation of the potential effects of combination 
therapy on lung and systemic inﬂ  ammation may also lead to 
modiﬁ  cations to these recommendations. More importantly, 
understanding of the mechanisms by which FP interacts 
with Sal may provide ideas as to the development of 
improved combination therapies for greater efﬁ  cacy. Once-
daily combination therapy in COPD using longer-acting 
corticosteroids and β2-adrenergic agonists may be the next 
step in this direction. 
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